Fact-checked by Grok 2 weeks ago

Neuroenhancement

Neuroenhancement refers to the non-therapeutic enhancement of cognitive, emotional, or motivational functions in healthy individuals through pharmacological, neurotechnological, or behavioral means, aiming to exceed baseline performance levels.^[1] Common pharmacological approaches include stimulants such as modafinil, which improves alertness and executive function in sleep-deprived states but shows variable effects in well-rested healthy users, and methylphenidate, which may boost attention and working memory under specific conditions.^[2] Non-pharmacological methods encompass transcranial direct current stimulation (tDCS) for modulating cortical excitability to potentially enhance learning or decision-making, though evidence for robust, transferable gains remains inconsistent across studies.^[3] Lifestyle interventions like aerobic exercise and optimized sleep demonstrably support cognitive resilience and neuroplasticity via mechanisms including increased hippocampal volume and neurogenesis.^[1] Prevalence is notable among students and professionals, with surveys indicating 5-35% self-reported use of cognitive enhancers for academic or occupational demands, often driven by competitive pressures rather than proven necessity.^[4] Efficacy debates center on modest, context-dependent benefits overshadowed by placebo effects, individual variability, and risks like dependency, cardiovascular strain from stimulants, or unknown long-term neural impacts from repeated stimulation.^[2] Ethical controversies include distributive inequities exacerbating social divides, potential coercion in high-stakes environments, authenticity concerns regarding altered agency, and regulatory gaps amid off-label prescribing and unregulated devices.^[5]^[6] Future directions involve genetic interventions and advanced brain-computer interfaces, raising amplified safety and equity challenges without clear empirical precedents for broad societal integration.^[1]

Definition and Historical Development

Core Definition and Scope

Neuroenhancement encompasses interventions designed to augment cognitive, affective, or behavioral functions in healthy individuals, extending performance beyond baseline capabilities without addressing underlying pathology.^[7] This includes pharmacological agents, neurostimulation techniques, and other modalities that target neural processes such as attention, memory consolidation, executive control, and motivation, often in non-medical contexts like academic or professional demands.^[1] Unlike therapeutic applications, which restore function impaired by disease or injury—such as antidepressants alleviating clinical depression—neuroenhancement operates on unimpaired systems, raising distinct considerations for safety, equity, and long-term neural adaptation.^[8]^[9] The scope of neuroenhancement is delineated by its focus on elective, performance-oriented gains rather than normalization, excluding routine training or education as primary mechanisms unless augmented by targeted interventions.^[10] Core domains include cognitive enhancement (e.g., improved working memory or problem-solving), emotional enhancement (e.g., modulated mood stability or resilience), and instrumental uses for productivity, though overlaps with therapeutic boundaries can blur in borderline cases like mild cognitive complaints.^[1] Empirical definitions emphasize augmentation of "core information processing systems" in the brain, distinct from natural variability or environmental adaptations, with prevalence estimates indicating widespread non-prescribed use among students and professionals—up to 20% in some surveyed cohorts as of 2021.^[2]^[4] This framework prioritizes causal mechanisms rooted in neurobiology, such as modulation of neurotransmitters (e.g., dopamine via stimulants) or synaptic plasticity, but requires scrutiny of claims given variable efficacy across individuals and tasks; for instance, systematic reviews highlight modest, domain-specific benefits in healthy subjects rather than broad-spectrum gains.^[1] Scope limitations exclude enhancements via general health practices (e.g., sleep optimization) unless they involve novel neural interventions, and ethical discourse underscores the therapy-enhancement divide's moral salience, with public surveys from 2016 affirming greater acceptability for restorative uses over elective boosts.^[11] Ongoing research as of 2023 integrates these into broader neurotechnology paradigms, yet demands rigorous, placebo-controlled validation to distinguish genuine enhancement from placebo or expectancy effects.^[12]

Historical Origins and Evolution

The pursuit of cognitive enhancement through pharmacological means traces its roots to ancient civilizations, where natural substances such as caffeine from coffee and tea plants, as well as nicotine from tobacco, were employed to sustain alertness and mental stamina during prolonged activities.^[13] These early biochemical interventions, often derived from plants, represented rudimentary forms of neuroenhancement by counteracting fatigue and sharpening focus, though their mechanisms were not understood until modern neuroscience.^[14] Instrumental use of such agents for adaptive purposes, including heightened performance in labor or ritual, has parallels in non-human animal behavior, underscoring a deep evolutionary precedent for altering cognition via exogenous compounds.^[4] The modern era of synthetic cognitive enhancers began with the development of amphetamines in the early 20th century, following the isolation of amphetamine in 1910 and its initial medical applications for conditions like narcolepsy in the 1930s.^[15] Non-medical use for academic performance emerged concurrently, with reports of amphetamine as a "study drug" documented as early as the 1930s among students seeking improved concentration and memory retention.^[16] During World War II, amphetamines were extensively deployed by military forces on both sides to combat fatigue and enhance vigilance; German troops received Pervitin (methamphetamine) to support extended operations, while Allied forces, including British and American units, adopted Benzedrine for similar wakefulness-promoting effects, distributing millions of doses to pilots and soldiers.^[17] ^[18] This wartime application marked a pivotal shift, demonstrating organized, large-scale use of stimulants for performance optimization under duress, though it also foreshadowed risks like dependency and post-war abuse epidemics.^[19] The formal conceptualization of neuroenhancement advanced in the mid-20th century with the synthesis of piracetam in 1964 by Corneliu E. Giurgea at UCB Pharma, initially targeted for motion sickness but observed to bolster learning and memory in animal models.^[20] Giurgea coined the term "nootropic" in 1972 to denote a novel class of agents that selectively enhance cognitive functions—such as memory consolidation and resistance to impairments—without the typical psychostimulant side effects of amphetamines, emphasizing safety and specificity to higher brain processes.^[21] ^[22] This innovation spurred the racetam family of compounds and broadened research into targeted enhancers, evolving from broad-spectrum stimulants to more refined modulators of neuroplasticity and neurotransmission. By the late 20th century, off-label use of prescription drugs like methylphenidate (Ritalin, approved 1955 for ADHD) among healthy individuals further propelled the field, reflecting a cultural shift toward elective cognitive augmentation amid growing awareness of brain chemistry's malleability.^[15] The trajectory continued into non-pharmacological domains, with historical precedents for electrical brain stimulation dating to the 18th-19th centuries in Europe and the U.S., laying groundwork for contemporary techniques like transcranial direct current stimulation.^[3]

Pharmacological Approaches

Primary Agents and Their Profiles

Modafinil, chemically known as 2-[(diphenylmethyl)sulfinyl]acetamide, is a eugeroic drug approved by the U.S. Food and Drug Administration (FDA) in 1998 for treating narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Off-label, it is among the most commonly used agents for pharmacological neuroenhancement in healthy individuals, particularly for enhancing wakefulness, attention, and executive functions during periods of fatigue or high cognitive demand.^[2] A 2015 systematic review of 24 studies found that modafinil improves complex cognitive tasks such as planning and decision-making in non-sleep-deprived healthy adults, though effects on creativity and memory are inconsistent.^[23] Evidence indicates limited enhancement potential outside sleep-deprived contexts, with benefits primarily in vigilance and inhibitory control rather than broad cognitive uplift.^[24] Methylphenidate, a central nervous system stimulant and dopamine-norepinephrine reuptake inhibitor, received FDA approval in 1955 for attention deficit hyperactivity disorder (ADHD) and narcolepsy, with extended-release formulations approved later for adults. In healthy populations, it is frequently employed off-label for neuroenhancement, especially among students and professionals seeking improved focus and working memory.^[25] A review of placebo-controlled trials reported positive effects on working memory (65% of studies) and inhibitory control in healthy volunteers, though outcomes vary by baseline cognitive performance and dosage, with higher performers showing smaller gains.^[26] Off-label use raises concerns due to potential for abuse, as it is classified as a Schedule II controlled substance in the U.S.^[27] Amphetamines, including dextroamphetamine and mixed amphetamine salts (e.g., Adderall, approved by the FDA in 1996 for ADHD and narcolepsy), act primarily as dopamine and norepinephrine releasers. These agents are sought for neuroenhancement to boost motivation, sustained attention, and verbal learning in healthy users, with systematic reviews documenting strong effects on vigilance and delayed memory recall.^[28] Unlike modafinil, amphetamines exhibit a narrower therapeutic window in non-clinical populations, with efficacy tied to catecholamine modulation but tempered by risks of tolerance and dependency; studies show benefits predominantly under high-load tasks rather than routine cognition.^[29] Prevalence data from surveys indicate amphetamines as a top choice alongside methylphenidate for academic performance enhancement.^[1]

Neurobiological Mechanisms

Pharmacological neuroenhancers exert their effects primarily through modulation of catecholaminergic systems, including dopamine and norepinephrine, which influence attention, working memory, and executive function in prefrontal cortical regions. These agents typically target transporters or release mechanisms to elevate extracellular neurotransmitter levels, enhancing signal transmission in circuits underlying cognition.^[2] ^[30] Methylphenidate, a common stimulant used for cognitive enhancement, inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake and thereby increasing synaptic concentrations of dopamine and norepinephrine, with preferential effects in the prefrontal cortex (PFC) at low, cognition-enhancing doses. This elevation optimizes PFC-dependent processes via interactions with dopamine D1 receptors and α2 adrenoceptors, improving signal-to-noise ratios in neural firing patterns critical for working memory and inhibitory control.^[31] ^[32] ^[33] Modafinil promotes wakefulness and cognitive performance by weakly inhibiting DAT, resulting in increased dopamine release and efflux in dorsal and ventral striatal areas, alongside dependence on intact dopaminergic and adrenergic pathways for its arousing effects. It also suppresses GABAergic neurotransmission centrally, potentially amplifying excitatory signaling, and may activate orexin neurons in the hypothalamus to sustain vigilance without the stereotyped behaviors seen in classical stimulants.^[34] ^[35] ^[36] Amphetamine derivatives, such as those in Adderall formulations, facilitate the reverse transport of dopamine and norepinephrine across vesicular and plasma membranes, promoting their presynaptic release and inhibiting reuptake, which heightens catecholamine availability in mesocortical and mesolimbic pathways to bolster motivation and attentional focus. These mechanisms collectively underscore the reliance on monoaminergic enhancement for neuroenhancement, though individual variability in transporter expression and receptor sensitivity modulates efficacy.^[2] ^[37]

Empirical Evidence on Efficacy

Empirical studies on pharmacological neuroenhancement in healthy adults reveal modest, domain-specific improvements rather than broad cognitive gains. A 2020 meta-analysis of randomized controlled trials found that modafinil, methylphenidate (MPH), and d-amphetamine produced small enhancements in attention and memory for non-sleep-deprived individuals, with effect sizes typically below 0.3 standard deviations, but no consistent benefits across all cognitive domains.^[38] These effects were more pronounced under conditions of fatigue or high cognitive load, suggesting limited utility for baseline enhancement in rested subjects.^[39] Modafinil demonstrates the most consistent evidence among wakefulness-promoting agents, improving attention, executive function, and planning in healthy non-sleep-deprived adults. A 2015 meta-analysis of 24 studies reported significant positive effects on short-term memory, executive function, and attention, with standardized mean differences ranging from 0.10 to 0.77, though overall pooled effects remained small and were influenced by factors like baseline performance.^[23] In well-rested participants, modafinil enhanced wakefulness and selective aspects of cognition without adversely affecting mood, but failed to improve creativity or broad intelligence measures.^[40]^[41] Stimulants such as MPH and amphetamines yield mixed results, often confined to working memory and inhibitory control. Systematic reviews indicate that single doses of MPH improve working memory in 65% of studies on healthy volunteers, alongside gains in reaction time and decision-making, yet these do not translate to superior real-world outcomes like exam performance.^[26]^[42] D-amphetamine similarly boosts attention and vigilance but shows only small cognitive effects in young adults, with users overestimating benefits due to heightened subjective alertness rather than objective gains.^[43] A 2023 study further highlighted that amphetamines increase motivation for effortful tasks but may impair solution quality in complex problem-solving, potentially offsetting net benefits.^[44] Methodological limitations temper these findings, including small sample sizes (often n<50), short-term dosing, and publication bias favoring positive results, which may inflate perceived efficacy. No high-quality evidence supports sustained, transferable enhancements from these agents in healthy populations, with effects often reverting to baseline post-administration and varying by genetic factors like COMT polymorphisms.^[38]^[29] Overall, pharmacological neuroenhancement provides marginal advantages in specific scenarios but lacks robustness for general cognitive uplift.

Non-Pharmacological Approaches

Electrical and Magnetic Stimulation

Electrical stimulation techniques, such as transcranial direct current stimulation (tDCS), deliver low-intensity direct currents (typically 1-2 mA) through scalp electrodes to modulate neuronal excitability without inducing action potentials. Anodal stimulation hyperpolarizes resting membrane potentials to facilitate neuronal firing and enhance synaptic plasticity akin to long-term potentiation (LTP), while cathodal stimulation inhibits excitability; sessions commonly last 20-30 minutes targeting regions like the dorsolateral prefrontal cortex (DLPFC) for executive functions.^[45]^[46] Empirical evidence for tDCS-induced cognitive enhancement in healthy adults remains limited and inconsistent, with meta-analyses showing no reliable improvements in working memory capacity despite initial promising reports. Transcranial alternating current stimulation (tACS), a variant applying oscillatory currents to entrain neural rhythms, demonstrated small but significant gains in cognitive tasks like attention and memory in young healthy participants across a 2023 meta-analysis of 33 studies involving over 1,000 subjects. However, effects are task-specific, short-lived (often <1 hour post-stimulation), and susceptible to inter-individual variability influenced by factors such as electrode montage and baseline performance, with replication challenges highlighting potential overestimation due to small sample sizes and publication bias.^[47]^[48] Magnetic stimulation, primarily repetitive transcranial magnetic stimulation (rTMS), uses pulsed magnetic fields (intensities 80-120% of motor threshold) to induce focal electric currents in cortical tissue, promoting neuroplasticity through high-frequency (≥5 Hz) excitatory protocols that mimic LTP or low-frequency (≤1 Hz) inhibitory ones. Targeting the DLPFC or parietal areas, rTMS has yielded modest cognitive benefits in healthy subjects, including improved working memory and response inhibition in a 2019 review synthesizing data from multiple randomized trials, though effect sizes (Cohen's d ≈ 0.3-0.5) are smaller than in clinical populations like those with mild cognitive impairment.^[49]^[50] Both modalities exhibit favorable safety profiles in healthy adults when adhering to guidelines: tDCS evokes transient sensations like mild tingling or itching in 40-70% of users, with no serious adverse events reported in thousands of sessions; rTMS commonly causes scalp discomfort or headaches (20-30% incidence), with seizure risk below 0.1% in screened individuals lacking contraindications like epilepsy or metal implants. Long-term risks remain understudied, but acute tolerability supports repeated use; methodological limitations, including sham control inadequacies and heterogeneous protocols, underscore the need for larger, standardized trials to substantiate enhancement claims beyond placebo.^[51]^[52]

Digital and Behavioral Interventions

Digital interventions for neuroenhancement encompass computerized cognitive training programs and neurofeedback applications, which aim to improve cognitive domains such as attention, memory, and executive function through interactive software or real-time brain activity monitoring. A meta-analysis of standalone digital cognitive interventions reported small-to-moderate positive effects on overall cognition and mental health in diverse populations, though effects on fatigue and quality of life were marginal.^[53] Computerized cognitive training has demonstrated efficacy in enhancing executive function among patients with traumatic brain injury, with a standardized mean difference of 0.32.^[54] However, in healthy individuals, evidence for broad transfer to untrained tasks remains limited, with meta-analyses indicating superior outcomes for strategy-based training over passive controls but questioning generalizability beyond specific trained skills.^[55] Neurofeedback, often delivered via mobile apps or EEG-based systems, trains users to modulate brain waves for cognitive gains, showing reproducible evidence of behavioral and cortical plasticity that enhances performance in attention and memory tasks.^[56] Reviews highlight its potential in clinical settings like ADHD, where it improves neuropsychological outcomes, but applications for healthy cognitive enhancement require further validation due to variability in protocols and indirect causality pathways.^[57]^[58] Behavioral interventions include structured practices like mindfulness meditation and physical exercise, which leverage neuroplasticity without technological aids. Mindfulness-based interventions yield small-to-moderate improvements in global cognition, executive attention, working memory accuracy, and inhibition, particularly in meditation-naïve participants across 111 randomized trials.^[59] Yet, large-scale trials in older adults found no significant cognitive benefits from mindfulness training compared to exercise or combined approaches, underscoring domain-specific and population-dependent effects.^[60] Aerobic and multicomponent exercise consistently enhance general cognition, memory, and executive function across ages and populations, with meta-meta-analyses confirming benefits for executive tasks via mechanisms like increased BDNF expression.^[61] Spaced repetition, a behavioral learning technique involving timed reviews to optimize retention, outperforms massed practice in long-term memory consolidation and problem-solving, as evidenced by policy reviews synthesizing diverse learning paradigms.^[62] Studies in medical education affirm its efficacy for clinical knowledge retention, with spaced schedules yielding higher accuracy than daily repetition.^[63] These interventions' accessibility contrasts with pharmacological methods, but their sustained benefits depend on adherence and individual baseline cognition, with methodological challenges like small effect sizes and potential placebo influences warranting cautious interpretation in non-clinical enhancement contexts.^[64]

Nutritional and Lifestyle Factors

Nutritional interventions targeting cognitive enhancement often focus on specific macronutrients and micronutrients that support neuronal integrity and synaptic plasticity. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have demonstrated modest benefits in improving global cognitive function and reducing the risk of cognitive decline by approximately 20% in observational studies, with supplementation showing positive effects on memory and executive function in healthy older adults through mechanisms involving enhanced brain blood flow and neuroprotection.^[65]^[66] Creatine monohydrate supplementation, at doses typically around 5 grams daily, enhances cognitive performance in adults, particularly under conditions of mental fatigue or sleep deprivation, by supporting adenosine triphosphate availability in brain tissue.^[67] Caffeine, consumed via natural sources like coffee at low to moderate doses (40-300 mg), improves attention, reaction time, and executive function in a dose-dependent manner, with effects peaking within 30-60 minutes and persisting for hours, though benefits diminish at higher doses exceeding 400 mg due to increased anxiety.^[68]^[69] Ketogenic diets, which induce ketosis by restricting carbohydrates to under 50 grams daily and emphasizing fats, provide ketones as an alternative brain fuel, potentially stabilizing neural metabolism and improving working memory and attention in preliminary clinical trials, especially among individuals with metabolic impairments or early neurodegenerative conditions.^[70]^[71] The MIND diet, combining elements of Mediterranean and DASH diets with emphasis on berries, leafy greens, and nuts, correlates with enhanced global cognition, memory, and executive function in systematic reviews of older adults, attributing gains to reduced inflammation and oxidative stress.^[72] However, effects vary by baseline nutritional status, with stronger evidence in deficient populations for micronutrients like iron and iodine supporting fluid intelligence.^[73] Lifestyle factors such as aerobic exercise promote neuroenhancement through increased hippocampal volume, neurogenesis, and improved executive function, with meta-analyses indicating modest gains in attention, processing speed, and memory following regular sessions of 30-45 minutes at moderate intensity, three to five times weekly.^[74]^[61] Acute bouts of high-intensity aerobic exercise also facilitate cognitive performance immediately post-exercise, reducing reaction times via enhanced prefrontal cortex activation.^[75] Adequate sleep duration, optimally 6-8 hours per night, associates with preserved cognitive trajectories, exhibiting a U-shaped curve where both short (<6 hours) and long (>9 hours) durations predict greater decline in global cognition and executive function over longitudinal follow-up.^[76]^[77] Transitions from short to moderate sleep durations yield measurable improvements in cognitive scores.^[78] Mindfulness meditation practices, involving 10-20 minutes daily of focused attention or open monitoring, bolster executive control and working memory, with brief training (e.g., 4-8 weeks) enhancing Stroop task performance and reducing emotional interference in attention allocation, as evidenced by functional connectivity changes in frontoparietal networks.^[79]^[80] Combined interventions, such as diet paired with exercise, amplify effects on neuroplasticity via synergistic molecular pathways like BDNF upregulation and reduced neuroinflammation.^[81] These factors' efficacy depends on adherence and individual variability, with stronger outcomes in those with suboptimal baselines.^[82]

Scientific Validation and Research Landscape

Key Studies and Meta-Analyses

A 2020 meta-analysis of randomized controlled trials evaluated the cognitive effects of modafinil, methylphenidate (MPH), and d-amphetamine in healthy, non-sleep-deprived adults, analyzing 48 studies with over 1,400 participants. It found small, domain-specific enhancements: modafinil improved attention (Hedges' g = 0.12, 95% CI [0.02, 0.22]), MPH enhanced memory (g = 0.21, 95% CI [0.08, 0.34]), and d-amphetamine facilitated set-shifting tasks, but no broad-spectrum benefits across cognition, with effects moderated by baseline performance where low performers benefited more.^[38]^[29] Earlier, a 2015 systematic review and qualitative synthesis of 24 studies on modafinil in rested healthy adults reported consistent improvements in executive functions, including planning/decision-making (effect sizes 0.2-0.5 in key tasks like Tower of London), attention, and learning, without significant memory gains in non-sleep-deprived states; however, a 2019 meta-analysis of 14 trials challenged broader efficacy, concluding limited enhancement potential beyond sleep deprivation (overall g = 0.10, p < 0.05, but heterogeneous and small).^[41]^[23]^[24] For non-pharmacological methods, a 2016 meta-analysis of 20 transcranial direct current stimulation (tDCS) studies on working memory in healthy adults yielded a small overall effect (Hedges' g = 0.29, 95% CI [0.12, 0.46]), strongest for anodal dorsolateral prefrontal stimulation combined with training, though publication bias and protocol variability reduced reliability.^[83] A 2022 meta-analysis of tDCS for attention enhancement confirmed modest gains in sustained attention (g = 0.25, 95% CI [0.14, 0.36]) across 15 trials, but effects were inconsistent for healthy populations without impairment.^[84] Similarly, a 2015 meta-analysis of aerobic exercise interventions (n=29 studies, >2,000 healthy adults) demonstrated moderate improvements in executive function (g = 0.24) and memory (g = 0.18), linked to neurogenesis and BDNF upregulation, outperforming controls in longitudinal designs.^[85] These findings highlight that while select interventions yield statistically significant but small-to-moderate effects (typically g < 0.3), replication issues, small sample sizes (often n<50 per arm), and ceiling effects in high-ability individuals limit generalizability, with no single method achieving robust, transferable enhancement across diverse cognitive domains.^[38]^[83]

Methodological Challenges and Biases

Research on neuroenhancement, encompassing both pharmacological and non-pharmacological interventions, frequently encounters methodological hurdles that undermine the reliability of findings. A primary issue is the prevalence of small sample sizes, typically ranging from 8 to 52 participants in key trials on agents like modafinil or techniques such as transcranial direct current stimulation (tDCS), which reduce statistical power and hinder generalizability to broader populations.^[1] Additionally, many studies employ short-term, single-dose designs or lack rigorous double-blinded, placebo-controlled protocols, constrained by ethical concerns over repeated substance administration in healthy volunteers, leading to overreliance on observational or self-report data that introduces confounding variables like motivation and expectation.^[1] ^[21] Replication challenges exacerbate these design flaws, with systematic reviews revealing inconsistent effects across studies; for instance, stimulants and modafinil yield mixed results on memory and executive function, while non-invasive brain stimulation outcomes vary widely due to protocol differences.^[1] This inconsistency aligns with broader reproducibility issues in psychopharmacology, where the complexity of neural mechanisms—lacking reliable biomarkers for healthy cognition—complicates causal attribution beyond therapeutic contexts for impaired individuals.^[86] Placebo effects further obscure true efficacy, as expectations of enhancement can boost both perceived and objective cognitive performance in trials, yet few incorporate adequate controls to disentangle these from pharmacological actions.^[87] ^[88] Measurement validity poses another barrier, with heterogeneous cognitive tasks and outcome metrics—ranging from subjective self-reports to objective tests like verbal fluency—lacking standardization, often resulting in perceived benefits outpacing empirical gains, as seen in 70% of methylphenidate users reporting positives despite modest lab-verified improvements.^[1] Research disproportionately targets populations with cognitive deficits rather than healthy individuals seeking enhancement, limiting applicability to prophylactic use and introducing selection biases from volunteer samples prone to overconfidence.^[21] Biases compound these challenges, including publication bias favoring positive results, which distorts meta-analytic evidence in neurosciences and cognitive domains by underrepresenting null findings.^[89] ^[90] Industry funding from pharmaceutical entities may amplify optimistic reporting, while academic incentives prioritize novel enhancements over null replications, potentially overlooking long-term null or adverse effects in healthy cohorts where evidence remains sparse and conflicting.^[21] ^[86] These systemic issues, rooted in empirical and structural realities rather than ideological distortions, necessitate larger, preregistered trials with diverse demographics to better isolate causal mechanisms.^[91]

Health Risks and Safety Profile

Acute and Physiological Effects

Pharmacological neuroenhancers, including modafinil, methylphenidate, amphetamines, and caffeine, produce acute physiological effects through enhanced monoaminergic neurotransmission, particularly dopamine and norepinephrine, which elevate central nervous system arousal and sympathetic activity.^[2] These changes manifest as increased heart rate and blood pressure across stimulants, with modafinil demonstrating dose-dependent elevations in both metrics comparable to cocaine at higher doses.^[92] Methylphenidate similarly induces dopamine and norepinephrine efflux in prefrontal cortex and striatal regions via reuptake inhibition, potentiating neuronal firing and NMDA-mediated transmission.^[93] Cardiovascular strain is a common acute risk, with amphetamines and methylphenidate raising systolic and diastolic blood pressure alongside tachycardia, even at therapeutic doses used for enhancement.^[94] Caffeine at moderate doses (200-300 mg) boosts alertness and vigor without severe hemodynamic shifts but elevates systolic blood pressure by up to 11 mm Hg in caffeine-naïve individuals, while higher doses (600 mg) provoke jitteriness, tension, and further pressor responses.^[95] Amphetamines additionally trigger acute agitation, appetite suppression, and insomnia, with potential for early neurochemical disruptions like striatal dopamine transporter occupancy.^[94] Adverse central effects include anxiety, headache, and motor restlessness from modafinil and methylphenidate, often tied to hyperdopaminergic states, though these agents generally spare severe hyperarousal in healthy users compared to traditional amphetamines.^[2] Caffeine enhances reaction time and mood transiently but risks anxiety at supratherapeutic levels, underscoring dose-dependent trade-offs in physiological homeostasis during acute use for cognitive boosting.^[95] Studies in non-clinical populations highlight these effects' variability, influenced by baseline arousal and tolerance, with limited evidence of outright toxicity at single low-to-moderate doses but consistent autonomic activation.^[93]^[94]

Chronic and Dependency Risks

Long-term use of pharmacological neuroenhancers, particularly stimulants such as amphetamines and methylphenidate, carries risks of tolerance development, where escalating doses are required to achieve initial cognitive effects due to neuroadaptations in dopamine signaling pathways.^[96] In non-ADHD populations seeking enhancement, chronic methylphenidate administration has been linked to altered brain chemistry, including heightened risk-taking behaviors and persistent sleep disruptions, potentially exacerbating cognitive deficits over time.^[97] Amphetamines similarly induce patterns of cognitive impairment in chronic users, with evidence of perseverative behaviors, psychomotor changes, and reduced executive function persisting beyond acute intoxication.^[98] These effects stem from repeated overstimulation of reward circuits, fostering physical dependence characterized by withdrawal symptoms like fatigue and anhedonia upon cessation.^[94] Dependency risks are notably higher for dopaminergic agents like amphetamines compared to other classes; meta-analyses indicate no broad cognitive enhancement from amphetamines in healthy individuals, yet their reinforcing properties drive non-medical misuse, with up to 10-20% of college students reporting tolerance after repeated off-label use.^[99] Methylphenidate exhibits reinforcing effects primarily in those without ADHD, increasing subjective "high" and motivation for continued use, though less so than amphetamines.^[100] Cardiovascular strain from chronic stimulant exposure, including elevated blood pressure and potential arrhythmias, compounds these issues, with longitudinal data showing heightened morbidity in non-prescribed users.^[101] In contrast, modafinil demonstrates lower dependency potential, with clinical trials reporting minimal euphoric reinforcement or withdrawal in healthy users, attributed to its distinct mechanism involving orexin and histamine modulation rather than direct dopamine release.^[102] However, prolonged modafinil use may disrupt natural sleep architecture, leading to cumulative deficits in restorative processes and indirect cognitive decline, as observed in studies of shift workers using it for vigilance.^[103] Broader nootropic classes, including racetams or caffeine analogs, show variable tolerance but rare addiction, though empirical data on decades-long use remains sparse, limiting definitive assessments of subclinical neurological wear.^[21] Overall, while acute safety profiles vary, chronic risks underscore the need for caution in non-therapeutic contexts, as self-medication often evades monitoring for dose escalation or interactions.^[2]

Ethical and Philosophical Debates

Pro-Enhancement Arguments: Liberty and Progress

Proponents of neuroenhancement emphasize individual liberty, contending that autonomous adults hold the right to employ cognitive enhancers to optimize their mental faculties, akin to pursuing education or physical training, without undue paternalistic restrictions from government or society. This view posits that personal autonomy encompasses the freedom to accept calculated risks for potential self-improvement, provided enhancements do not infringe on others' rights or public safety.^[104] Libertarian arguments further reject bans on neuroenhancement as overreach, arguing that evolutionary pressures favor adaptive self-modification, and coercive prohibitions undermine human agency more than the enhancements themselves.^[105] Such liberty extends to cognitive freedom, where individuals should control their mental states and capacities, resisting mandates that limit enhancement to preserve a supposed "natural" baseline, which critics deem arbitrary and anti-progressive. Bioethicists like those advocating transhumanist principles frame this as an extension of historical human endeavors to transcend biological limits, from tools to medicine, asserting that denying enhancement equates to stagnation rather than ethical caution.^[106] In practice, this aligns with precedents where voluntary use of stimulants like modafinil for wakefulness has been tolerated among professionals, prioritizing user sovereignty over blanket moralizing.^[107] On progress, advocates argue neuroenhancement accelerates human advancement by amplifying intelligence and creativity, yielding societal gains such as reduced cognitive deficits' economic costs—estimated at trillions globally—and boosted innovation in fields like research and engineering. Empirical models suggest widespread adoption could enhance GDP through productivity surges, with cognitive boosts correlating to higher output in knowledge economies, as seen in studies of enhanced focus yielding 10-20% task efficiency improvements.^[108] Transhumanists extend this to long-term evolution, viewing enhancements as imperative for competing with artificial intelligence and solving existential challenges, thereby fulfilling a moral duty to elevate human potential beyond current biological constraints.^[109] Philosophers including Julian Savulescu contend that failing to pursue enhancement constitutes a dereliction of responsibility, as superior cognition enables better decision-making and ethical outcomes, paralleling obligations to vaccinate or educate for collective welfare. This progress-oriented rationale posits neuroenhancement not merely as optional but as a catalyst for paradigm shifts, potentially averting stagnation in an era demanding rapid adaptation to technological and environmental pressures.^[110] Critics of anti-enhancement stances highlight how such views, often rooted in egalitarian fears, overlook evidence that targeted enhancements have historically driven breakthroughs, from caffeine's role in the Enlightenment to nootropics in modern R&D.^[104]

Anti-Enhancement Critiques: Equality and Authenticity

Critics of neuroenhancement contend that widespread adoption would exacerbate social inequalities by privileging those with financial means to access enhancers, such as prescription stimulants or nootropics, thereby widening gaps in cognitive performance and socioeconomic outcomes between enhanced elites and others.^[111] This concern draws from distributive justice arguments, positing that enhancements function as a new form of positional good, where benefits accrue disproportionately to the affluent, potentially entrenching class divisions rather than merit-based advancement.^[112] Empirical surveys of public attitudes reveal consistent worries about equality of opportunity, with respondents viewing unequal access as a primary ethical barrier to pharmacological cognitive enhancement.^[111] A related critique highlights the risk of coercion, where non-users face competitive pressures in high-stakes environments like education or employment, effectively normalizing enhancement and diminishing genuine autonomy.^[113] For instance, in academic settings, students might feel compelled to use substances like modafinil to match peers, transforming voluntary choice into de facto obligation and raising questions about informed consent under social duress.^[112] Proponents of this view, including bioethicists, argue that such dynamics could foster an "enhancement arms race," where baseline performance expectations inflate, coercing broader participation without addressing underlying inequalities in access or regulation.^[114] On authenticity, philosophers like Michael Sandel argue that neuroenhancement erodes the intrinsic value of human traits as "gifts" from nature, fostering a hubristic attitude that demands mastery over biological limits and diminishes appreciation for unchosen endowments.^[115] In The Case Against Perfection (2007), Sandel posits that treating cognition as a commodity for optimization undermines moral humility and the authenticity derived from accepting human vulnerability, potentially leading to a society that views individuals as self-made products rather than shaped by contingency.^[116] This perspective aligns with broader concerns that enhancements alter personal identity, as alterations to neural function—via drugs or neuromodulation—may disconnect achievements from one's core self, rendering success inauthentic and praise less deserved.^[117] Francis Fukuyama has similarly critiqued enhancement technologies, including neuroenhancement, as threats to human dignity by engineering away inherent limitations that define species essence, potentially homogenizing traits and eroding the authenticity of diverse human experiences.^[104] Critics like Carl Elliott extend this to pharmacological interventions, warning that substances altering mood or cognition, such as antidepressants repurposed for enhancement, could fabricate personalities that lack continuity with prior authentic states, prioritizing engineered ideals over organic development.^[118] Layperson opposition often echoes these views, with studies indicating that perceived threats to authenticity—framed as unnatural interference—underpin moral resistance to cognitive enhancement more than utilitarian risks alone.^[119]

Regulatory and Policy Considerations

Pharmacological neuroenhancers like modafinil and methylphenidate are regulated as prescription-only medications in the United States, classified under Schedule IV and II of the Controlled Substances Act by the Drug Enforcement Administration due to their potential for abuse and dependence. Non-medical use for cognitive enhancement in healthy individuals is illegal, as these substances are approved solely for treating conditions such as narcolepsy, shift-work sleep disorder, or attention-deficit/hyperactivity disorder. The Food and Drug Administration (FDA) has issued warnings to vendors marketing unapproved synthetic nootropics as dietary supplements, deeming them unapproved new drugs lacking evidence of safety and efficacy for enhancement purposes when sold without prescriptions. Natural nootropics, such as caffeine or certain herbal extracts, face lighter regulation under the Dietary Supplement Health and Education Act, though the FDA does not pre-approve their claims and has cracked down on products adulterated with undeclared pharmaceuticals. Internationally, regulatory frameworks vary, with many countries mirroring U.S. controls by restricting stimulants to medical prescriptions; for instance, modafinil requires authorization across the European Union under pharmaceutical laws, while non-prescribed distribution is penalized. In sports, the World Anti-Doping Agency (WADA) prohibits cognitive enhancers like modafinil and amphetamines during competitions, classifying them as stimulants with performance-boosting potential, enforceable through testing protocols adopted by signatory organizations. Academic institutions often extend prohibitions via honor codes or drug policies, viewing non-medical use as akin to cheating, though enforcement remains challenging absent universal detection methods. Policy debates center on balancing individual autonomy against public health risks, fairness in competitive domains, and the adequacy of current controls, which critics argue drive underground markets without addressing demand from high-achievers. Proponents of liberalization, including some ethicists, contend that informed adult use of safe enhancers should not be criminalized, akin to cosmetic enhancements, provided risks are disclosed, while opponents highlight coercion in pressure-cooker environments like workplaces or exams and unproven long-term safety for healthy brains. Governments have largely avoided comprehensive neuroenhancement policies, opting for case-by-case enforcement rather than outright bans on soft enhancers like racetams, amid evidence of rising off-label prevalence underscoring regulatory gaps.^[2]^[120]

Societal Prevalence and Impacts

Usage Statistics by Demographics

Pharmacological neuroenhancement exhibits varying prevalence across demographics, with the highest rates observed among university students, where lifetime usage estimates range from 2% to 43% depending on the study population, substance definition, and region, though 12-month prevalence is generally 5-20%.^[121] In contrast, general population surveys report lower figures, such as a 4.3% lifetime prevalence for stimulating prescription drugs used without medical indication in a representative German sample.^[122] Among specific professions in Germany, 12-month prevalence stands at 2.9%, with even lower 4-week rates of 1.3%.^[123] Gender differences consistently favor higher male usage; a systematic review of university students found males reporting over 2.5 times the prevalence of females in UK samples, while Brazilian student data showed 9% male versus 5.4% female methylphenidate misuse.^[121] An online survey of off-prescription modafinil users (n=219) revealed 86% were male.^[124] UK university students and staff during COVID-19 restrictions also showed males with elevated odds for substances like modafinil (52% usage rate) and prescription stimulants (60.3%).^[125] Age patterns indicate peak usage in young adulthood, with modafinil off-label users averaging 27 years (range 18-68) in self-reported surveys.^[124] Among students, younger subgroups (e.g., first-semester or under 21) report higher rates, such as 24.3% in early semesters versus declines in older groups.^[121] Prevalence decreases post-university, aligning with lower general adult rates. Educational and occupational factors correlate with elevated use among those in higher education or demanding fields; modafinil users were predominantly university-educated (43% undergraduate, 21% postgraduate degrees), with 46% full-time employed.^[124] Student surveys highlight higher prevalence in medicine, pharmacy, and sports-related studies (e.g., 8.7% in Iranian medical students, 25.4% in sports fields).^[121] Common substances include methylphenidate, amphetamines, and modafinil, often sourced informally for concentration and alertness amid academic or professional pressures.^[121] Self-reported data may underrepresent due to stigma, but patterns hold across peer-reviewed surveys.^[126]

Economic and Productivity Outcomes

Empirical studies on pharmacological neuroenhancers, such as modafinil and prescription stimulants like Adderall, indicate mixed effects on workplace productivity among healthy individuals without diagnosed conditions like ADHD. A meta-analysis of 24 studies found modafinil particularly enhances decision-making and planning capabilities, potentially aiding complex professional tasks under fatigue.^[127] However, recent experimental research demonstrates that stimulants including modafinil and methylphenidate often reduce overall efficiency in non-ADHD users, with participants expending greater effort and time on tasks while showing minor declines in accuracy.^[128] ^[129] In professional settings, self-reported use of these substances for performance enhancement is common, particularly among high-pressure fields like finance and technology, where workers seek to extend work hours or sustain focus during demanding periods.^[130] Yet, controlled trials reveal that such drugs can induce hyperfocus at the expense of task-switching flexibility, leading to erratic decision-making and prolonged completion times—up to 50% longer in some cases for methylphenidate—thus potentially undermining net productivity gains.^[131] No robust evidence supports broad cognitive improvements or smarter outcomes from Adderall in neurotypical adults, with benefits largely confined to those with attention deficits.^[132] Economically, proponents argue neuroenhancement could mitigate productivity losses from cognitive decline or suboptimal performance, potentially yielding societal benefits through reduced economic drags like early retirement or underperformance in knowledge economies.^[108] Counterarguments highlight hidden costs, including health expenditures from side effects, dependency risks, and widened inequalities if access favors higher socioeconomic groups, exacerbating divides without proportional GDP uplift.^[133] While modafinil shows promise in sustaining motivation for repetitive tasks, its workplace adoption raises concerns over coerced use in competitive environments, where short-term output boosts may not translate to sustainable economic value.^[134] ^[135] Overall, causal evidence leans toward limited or context-specific productivity enhancements, tempered by risks of diminished returns in healthy populations.

Emerging Frontiers

Advanced Neurotechnologies

Advanced neurotechnologies encompass invasive and semi-invasive interventions designed to interface directly with neural circuits, aiming to augment cognitive functions such as memory, attention, and decision-making in healthy individuals beyond baseline performance. These include brain-computer interfaces (BCIs) with implantable electrodes, deep brain stimulation (DBS) variants, and emerging optogenetic tools, distinguishing them from non-invasive methods like transcranial stimulation by their capacity for precise, bidirectional neural modulation. While primarily developed for therapeutic restoration in conditions like paralysis or dementia, their application to neuroenhancement raises questions of efficacy, as empirical evidence in non-clinical populations remains limited to preclinical models and small-scale trials.^[136]^[137] Prominent examples center on high-density electrode arrays, such as those from Neuralink, which received FDA approval for human trials in May 2023 after initial rejection. The company's PRIME study implanted its first device in a quadriplegic patient in January 2024, enabling thought-based control of a computer cursor at speeds up to 8 bits per second by late 2024, with ongoing expansions to speech decoding for impaired individuals as of April 2025. Although Neuralink's current trials target autonomy restoration rather than enhancement, founder Elon Musk has articulated long-term goals of cognitive augmentation, including seamless integration with artificial intelligence to exceed natural human limits. Independent analyses note that such systems detect neural activity with over 1,000 electrodes per thread, threaded robotically to minimize tissue damage, but scalability to healthy users for enhancement purposes lacks robust clinical validation.^[138]^[139]^[140] Evidence for cognitive enhancement via BCIs in healthy or aging populations is preliminary and mixed. A 2025 systematic review of EEG-based neurofeedback BCIs in older adults found improvements in attention and memory dynamics, attributing gains to targeted training of brain oscillations, though effects were modest (effect sizes <0.5) and not superior to traditional cognitive training in all metrics. Invasive approaches like DBS, adapted from Parkinson's treatment, have shown off-label memory boosts in epileptic patients via hippocampal stimulation, with one 2018 study reporting 15-20% recall improvements during targeted bursts, but risks of overstimulation include seizures and unintended mood alterations. Broader BCI applications in dementia patients demonstrated six-week cognitive gains outperforming sham controls, yet generalization to healthy enhancement is speculative, with no large-scale randomized trials confirming sustained benefits without deficits.^[141]^[142]^[143] Risks of invasive neurotechnologies include surgical complications, with Neuralink's implantation carrying a 10-15% infection rate in early animal models, alongside long-term concerns like electrode degradation and glial scarring reducing signal fidelity over months. Ethical analyses highlight mental privacy erosion, as decoded neural data could enable surveillance or coercion, with UNESCO's 2025 framework urging safeguards against non-consensual augmentation. Benefits, if realized, could include accelerated learning—projected 2-5x faster skill acquisition via direct neural feedback—but causal mechanisms remain understudied, with critics noting publication biases in industry-funded trials favoring positive outcomes over null results. Regulatory hurdles persist, as enhancement claims evade FDA oversight unlike therapeutic ones, potentially accelerating unvetted deployment.^[144]^[145]^[146]

Projected Societal Transformations

Advancements in neuroenhancement technologies, such as non-invasive brain-interfacing devices, are projected to integrate deeply into daily life by 2040, akin to the ubiquity of smartphones, enabling enhancements in attention, memory, mood regulation, and multi-person neural communication.^[147] These developments could render such technologies essential for learning and professional performance in well-resourced societies, potentially shifting societal norms toward viewing unenhanced cognition as a disadvantage.^[147] Unequal access to these enhancements is anticipated to amplify socioeconomic divides, as individuals or groups with resources to adopt them—such as pharmacological agents, transcranial direct current stimulation (tDCS), or neural implants—secure competitive edges in education, employment, and innovation.^[148] For instance, tDCS has demonstrated up to a 25% improvement in visual search task accuracy for responders, but response variability could disadvantage non-responders in high-stakes scenarios like academic exams or job interviews for roles requiring precision, such as surgery or piloting.^[149] This dynamic may foster a bifurcated society where enhanced elites dominate merit-based systems, prompting calls for state interventions like subsidized access to mitigate fairness erosion.^[149] ^[148] In the economic sphere, cognitive enhancements could drive productivity gains through reduced cognitive losses and amplified individual outputs, yielding broader societal benefits like accelerated innovation and GDP growth.^[148] However, projections warn of coercive pressures, with employers potentially mandating neurotech for job retention or advancement, blurring lines between voluntary improvement and compelled augmentation.^[147] Educational systems might evolve toward personalized neural augmentation for optimized learning trajectories, but without equitable distribution, this could entrench class-based cognitive disparities rather than democratize knowledge acquisition.^[147] Public sentiment reflects apprehension over these shifts, with 60% of Americans surveyed in 2022 anticipating widespread social pressure to adopt brain-chip enhancements if they become normalized, and 56% deeming such technologies detrimental to society overall due to risks of inequality and diminished authenticity.^[150] Experts emphasize preparatory regulatory frameworks, including global access initiatives and privacy safeguards, to avert dystopian outcomes where neuroenhancement reinforces rather than challenges existing power structures.^[147]

References

[1]
Neuroenhancement: State of the Art and Future Perspectives - PMC
Pharmacological neuroenhancement refers to the non-medical use of prescription drugs, alcohol, illegal drugs, or the so-called soft enhancers for the purpose ...
[2]
Pharmacological Neuroenhancement: Current Aspects of ...
Jan 13, 2021 · This review provides a comprehensive overview of the highly dynamic field of pharmacological neuroenhancement and elaborates the dramatic challenges
[3]
Non-invasive brain stimulation and neuroenhancement
The consensus among experts is that low-intensity tES is safe as long as tested and accepted protocols (including, for example, dose, inclusion/exclusion) are ...
[4]
Neuroenhancement as Instrumental Drug Use: Putting the Debate in ...
Sep 3, 2020 · The use of performance-enhancing drugs to study or work better is often called “cognitive enhancement” or “neuroenhancement” and sparked a debate between ...
[5]
Pharmacological Neuroenhancement: Current Aspects of ...
Jan 13, 2021 · The controversy of pNE mainly results from changing definitions of health and disease, the gradual transition from natural stimulants to ...6. Substance Groups · 6.5. Nootropics... · 8. Ethical Aspects Of Pne
[6]
The ethics of neuroenhancement - PubMed
Neuroenhancement raises ethical concerns about safety, compromised character, distributive justice, and coercion. There are no easy solutions to these concerns.Missing: controversies | Show results with:controversies
[7]
Bottom Up Ethics - Neuroenhancement in Education and Employment
May 1, 2018 · Neuroenhancement involves the use of neurotechnologies to improve cognitive, affective or behavioural functioning, where these are not ...
[8]
Distinguishing between Restoration and Enhancement in ...
The restoration-enhancement distinction becomes particularly relevant to the practicing physician in the context of safety—are the benefits afforded by the ...
[9]
Editorial: ELSI in Human Enhancement: What Distinguishes It From ...
This distinction should allow for a more nuanced appreciation of what is therapy and what is enhancement, where therapy relates to the maintenance or ...
[10]
Neuroenhancement - an overview | ScienceDirect Topics
Neuroenhancement refers to any augmentation of core information processing systems in the brain of healthy subjects, apart from natural training.
[11]
The is and ought of the Ethics of Neuroenhancement: Mind the Gap
Empirical support for the moral salience of the therapy-enhancement distinction in the debate over cognitive, affective and social enhancement. Neuroethics ...
[12]
On pharmacological neuroenhancement as part of the new ...
Jul 17, 2023 · We analyse and discuss some perspectives on cognitive enhancement, or “neuroenhancement”, which could be considered as part of enhancement neurotechnologies.
[13]
Hacking the Brain: Dimensions of Cognitive Enhancement - PMC
Biochemical enhancers with the longest tradition in human history are strategies to make use of certain nutritional components. Most widely used are probably ...Missing: timeline | Show results with:timeline
[14]
Brain augmentation and neuroscience technologies - NIH
Ever since the dawn of antiquity, people have strived to improve their cognitive abilities. From the advent of the wheel to the development of artificial ...
[15]
Stimulants: Abuse and Performance Enhancement (or Lack Thereof)
Jul 14, 2015 · Since the discovery of amphetamine in 1910 (1), stimulant drugs ... The illicit use of stimulants as cognitive enhancers has increased ...Missing: early | Show results with:early
[16]
How Realistic Are the Scientific Assumptions of ... - PubMed Central
Jan 22, 2018 · We identified publications documenting the use of amphetamine as study drugs, thus non-medically as neuroenhancement, as early as in the 1930s.Missing: origins | Show results with:origins
[17]
Amphetamine, past and present – a pharmacological and clinical ...
Amphetamines, i.e. racemic amphetamine, d-amphetamine and methamphetamine, were widely used to promote wakefulness in World War II, which in turn led to a large ...
[18]
the Allies' use of amphetamine during World War II - PubMed
The grounds on which amphetamine was actually adopted by both British and American militaries had less to do with the science of fatigue than with the drug's ...
[19]
Fast Times: The Life, Death, and Rebirth of Amphetamine
Apr 15, 2012 · Amphetamine use increased dramatically during World War II ... Some drugs combined amphetamine with barbiturates to control both mood and weight.
[20]
https://www.nooroots.com/blogs/nootropics-101/history-of-nootropics-supplements
[21]
Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects ...
Aug 17, 2022 · The term “nootropic” was first used by Cornelius E. Giurgea in 1972/1973 [10,11] to describe substances that primarily activate cognitive ...
[22]
The nootropic concept and its prospective implications - Giurgea
The nootropic concept emerged about 10 years ago essentially from the unusual pharmacology of piracetam, which later on was confirmed and extended to human ...
[23]
Review of 'smart drug' shows modafinil does enhance cognition
Aug 20, 2015 · Past studies on sleep-deprived individuals have shown a strong positive effect of modafinil on these functions, but there has been less ...
[24]
The Efficacy of Modafinil as a Cognitive Enhancer - PubMed
In conclusion, the available evidence indicates only limited potential for modafinil to act as a cognitive enhancer outside sleep-deprived populations.
[25]
Pharmacological Neuroenhancement in the Field of Economics ...
Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res. 62, 187–206. doi: 10.1016/j.phrs.2010.04.002.Missing: primary agents
[26]
Cognitive effects of methylphenidate in healthy volunteers: a review ...
The studies reviewed here show that single doses of MPH improve cognitive performance in the healthy population in the domains of working memory (65% of ...
[27]
Methylphenidate - StatPearls - NCBI Bookshelf - NIH
Off-label uses include cancer-related fatigue, refractory depression in older adults, apathy in patients with Alzheimer disease, and cognitive enhancement (eg, ...Continuing Education Activity · Indications · Administration · Monitoring
[28]
(PDF) Neuroenhancement in Healthy Adults, Part I - ResearchGate
Aug 10, 2025 · The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through inter alia ...
[29]
How effective are pharmaceuticals for cognitive enhancement in ...
R.M. Battleday et al. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review ... cognitive enhancement in non ...
[30]
The Cognition-Enhancing Effects of Psychostimulants Involve Direct ...
The clinical efficacy of these drugs is strongly linked to their ability to improve cognition dependent on the prefrontal cortex (PFC) and extended ...
[31]
Cognition-Enhancing Doses of Methylphenidate Preferentially ...
We recently demonstrated that low-dose methylphenidate (MPH) increases catecholamine efflux preferentially within the prefrontal cortex (PFC).
[32]
Methylphenidate improves prefrontal cortical cognitive function ...
Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in ...
[33]
Methylphenidate as a cognitive enhancer in healthy young people
Methylphenidate blocks the reuptake of dopamine and noradrenaline by blocking the transporters of these neurotransmitters, which leads to higher levels in the ...Missing: mechanisms | Show results with:mechanisms
[34]
Mechanisms of modafinil: A review of current research - PMC - NIH
They found that modafinil increased dopamine in the caudate and promoted arousal in the absence of orexin receptors, but modafinil had little effect in dopamine ...
[35]
Modafinil as a Catecholaminergic Agent: Empirical Evidence and ...
It binds competitively to the cell-membrane dopamine (DA) transporter and is dependent on catecholaminergic (dopaminergic and adrenergic) signaling for its wake ...
[36]
The neurobiology of modafinil as an enhancer of cognitive ...
Evidence for enhanced working memory, impulse control, vigilance and sustained attention in healthy volunteers has also been reported (Baranski et al. 2004; ...
[37]
The Pharmacology of Amphetamine and Methylphenidate
Methylphenidate actions include dopamine and norepinephrine transporter inhibition, agonist activity at the serotonin type 1A receptor, and redistribution of ...
[38]
How effective are pharmaceuticals for cognitive enhancement in ...
We examined cognitive performance in healthy non-sleep-deprived adults following modafinil, MPH, or d-amph vs placebo in 3 meta-analyses, using subgroup ...Missing: pharmacological | Show results with:pharmacological
[39]
Modafinil for cognitive neuroenhancement in healthy non-sleep ...
However, one agent, the FDA-approved eugeroic modafinil, has been extensively evaluated for cognitive modulation in healthy humans, and appears safe for ...
[40]
Modafinil and methylphenidate for neuroenhancement in healthy ...
Modafinil on the other hand, was found to improve attention for well-rested individuals, while maintaining wakefulness, memory and executive functions.
[41]
Lifestyle use of drugs by healthy people for enhancing cognition ...
Apr 20, 2017 · In support of their popularity, evidence from several meta-analyses validates the use of 'smart drugs' such as modafinil to enhance cognitive ...Drugs With Cognitive... · Novel Psychoactive... · Classes Of Drugs And...
[42]
Methylphenidate (Ritalin) does not improve exam performance in an ...
Aug 5, 2025 · For example, MPH most consistently improves working memory and processing speed, and some studies reported improved long-term episodic memory ( ...
[43]
Objective and subjective cognitive enhancing effects of mixed ...
We conclude that MAS has no more than small effects on cognition in healthy young adults, although users may perceive the drug as enhancing their cognition.
[44]
Not so smart? “Smart” drugs increase the level but decrease the ...
Jun 14, 2023 · Our findings suggest that “smart drugs” increase motivation, but a reduction in quality of effort, crucial to solve complex problems, annuls this effect.<|control11|><|separator|>
[45]
Neurobiological Mechanisms of Transcranial Direct Current ...
Transcranial direct current stimulation (tDCS) is a non-invasive method that modulates neural activities in the brain by delivering low-amplitude (usually no ...Missing: TMS | Show results with:TMS<|separator|>
[46]
Mechanisms and Effects of Transcranial Direct Current Stimulation
Feb 9, 2017 · Transcranial near-infrared has been used to improve memory in mice106 and improve cognitive function107 and mood108 in healthy human volunteers ...
[47]
Does Transcranial Direct Current Stimulation Improve Healthy ...
However, recent meta-analyses concluded that tDCS has little or no effect on WM in healthy participants. In this article, we review reasons why these meta- ...
[48]
A meta-analysis showing improved cognitive performance in healthy ...
Jan 3, 2023 · This systematic review and meta-analysis investigated the effects of tACS protocols on cognitive functions in healthy young adults.
[49]
Cognitive Enhancement in Neurological and Psychiatric Disorders ...
Feb 28, 2019 · The current review demonstrates that rTMS treatment has a significant effect in cognitive function across various groups including healthy and diseased ...<|separator|>
[50]
Transcranial magnetic stimulation: A review of its evolution and ...
Cognitive impairment has been researched the most in this population and evidence so far suggests that TMS may, in fact, have therapeutic benefits.[56] ...
[51]
Safety and recommendations for TMS use in healthy subjects and ...
Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines
[52]
Dosage and safety of transcranial magnetic stimulation and ...
Sep 9, 2025 · This scoping review aims to systematically identify and map the stimulation targets and stimulation dosages, and safety profiles of TMS and tDCS ...
[53]
Systematic review and meta-analysis of standalone digital ...
The meta-analysis found a small-to-moderate positive effect on cognition and mental health, with marginal effects on fatigue and quality of life.
[54]
The effectiveness of digital cognitive intervention in patients with ...
Oct 6, 2025 · The meta-analysis showed that digital cognitive interventions significantly improved executive function in TBI patients (SMD: 0.32, 95% CI ...
[55]
Review Comparative efficacy of cognitive training modalities in ...
Pairwise meta-analysis revealed that cognitive strategy training demonstrated superior to active control (AC) or passive control (PC) in improving language ...
[56]
Neurofeedback for cognitive enhancement and intervention and ...
Overall, there is thus ample reproducible evidence that neurofeedback can trigger behavioural and cortical plasticity changes that result in improved cognitive ...
[57]
Computerized cognitive training in attention-deficit/hyperactivity ...
Mar 29, 2023 · This meta-analysis investigated the effects of computerized cognitive training (CCT) on clinical, neuropsychological and academic outcomes ...
[58]
Can neurofeedback provide evidence of direct brain-behavior ...
Neurofeedback studies claim causality from brain activity to a cognitive function. However, causality in neurofeedback may also work through indirect means.Missing: apps | Show results with:apps
[59]
Mindfulness Enhances Cognitive Functioning: A Meta-Analysis of ...
This meta-analysis examined the effects of MBIs on global cognition and 15 cognitive subdomains. Inclusion criteria: meditation naïve participants; participants ...
[60]
Effects of Mindfulness Training and Exercise on Cognitive Function ...
Dec 13, 2022 · The findings do not support the use of mindfulness training, exercise, or a combination of both for significantly improving cognitive function in older adults.
[61]
a systematic umbrella review and meta-meta-analysis
Exercise interventions significantly improved general cognition, memory and executive function across all populations and ages. Those with attention-deficit/ ...
[62]
(PDF) Spaced Repetition Promotes Efficient and Effective Learning
Spaced review or practice enhances diverse forms of learning, including memory, problem solving, and generalization to new situations. Spaced practice is a ...
[63]
Effectiveness of spaced repetition for clinical problem solving ... - NIH
Jun 18, 2024 · A study of undergraduate medical students showed better short-term and long-term memory retention using spaced repetition learning [6].Missing: efficacy | Show results with:efficacy
[64]
Mindfulness training, cognitive performance and stress reduction
We have always had the obvious hypothesis that mindfulness practice will improve performance on incentivized tasks and lead to better psychological outcomes.
[65]
A systematic review and dose response meta analysis of Omega 3 ...
Aug 20, 2025 · Based on these pathways, long-chain omega-3 fatty acids (LCn-3s) are hypothesized to offer protective effects against cognitive decline.
[66]
Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions
Oct 9, 2022 · Ingestion of omega-3 fatty acids increases learning, memory, cognitive well-being, and blood flow in the brain.
[67]
The effects of creatine supplementation on cognitive function in adults
Jul 12, 2024 · Current evidence suggests that creatine monohydrate supplementation may confer beneficial effects on cognitive function in adults.
[68]
A review of caffeine's effects on cognitive, physical and occupational ...
The ability of caffeine to enhance cognitive and physical function is dose-dependent. Doses of approximately 0.5–4.0 mg kg−1 (∼40–300 mg) can improve cognitive ...
[69]
Exploring the impact of coffee consumption and caffeine intake on ...
Jul 1, 2025 · This study provides evidence of a positive correlation between coffee consumption, caffeine intake, and cognitive performance in older adults.
[70]
Effects of the ketogenic diet on cognition: a systematic review
Nov 10, 2022 · Discussion: Administration of KD seems to confer cognitive-enhancing effects in areas such as working memory, reference memory and attention.Missing: clinical | Show results with:clinical
[71]
Pilot study shows ketogenic diet improves severe mental illness
Apr 1, 2024 · A small clinical trial led by Stanford Medicine found that the metabolic effects of a ketogenic diet may help stabilize the brain.
[72]
The association between the MIND diet and cognitive health in ...
Jul 10, 2025 · This systematic review reveals the significant promise of the MIND diet in enhancing cognitive health, specifically in global cognition, memory, and executive ...
[73]
The effects of micronutrient interventions on cognitive performance ...
Micronutrient interventions showed significant positive effects on fluid intelligence in micronutrient-deficient children, especially iron and iodine deficient ...
[74]
Aerobic Exercise and Neurocognitive Performance: a Meta-Analytic ...
Aerobic exercise training is associated with modest improvements in attention and processing speed, executive function, and memory.
[75]
A systematic review and Bayesian meta-analysis provide evidence ...
Aug 28, 2024 · Multiple meta-analyses have observed that the effect of exercise is dependent on cognitive domain, with measures of executive function, ...
[76]
Sleep Duration and Cognitive Aging—Beyond a U-Shaped ...
Sep 21, 2020 · However, the association between sleep duration and cognitive function remains one of the most studied yet controversial topics, with ...
[77]
Prospective association between sleep duration and cognitive ... - NIH
We identified a U-shaped association of total sleep duration as well as nocturnal sleep duration with the risk of cognitive impairment.
[78]
Improvement in sleep duration was associated with higher cognitive ...
Oct 20, 2020 · A change from short sleep duration (SSD) to moderate sleep duration (MSD) was associated with better global cognition scores.
[79]
Meditation, mindfulness and executive control: the importance ... - NIH
Engaging in short-term meditation practice improves executive function, as measured by performance on the Stroop task (Wenk-Sormaz, 2005).
[80]
Mindfulness meditation improves cognition: Evidence of brief mental ...
Although research has found that long-term mindfulness meditation practice promotes executive functioning and the ability to sustain attention, the effects ...
[81]
The Combined Influences of Exercise, Diet and Sleep on ...
This review gathers evidence from molecular, systems and behavioral neuroscience to explain how these three key lifestyle factors influence neuroplasticity ...Missing: neuroenhancement | Show results with:neuroenhancement
[82]
Interventions involving a major dietary component improve cognitive ...
Interventions involving a major dietary component improve cognitive function in cognitively healthy adults: a systematic review and meta-analysis · Authors.
[83]
A meta-analytic study of exogenous oscillatory electric potentials in ...
A meta-analysis suggests that tDCS can improve working memory performance, but overall effect sizes are small (Hill et al., 2015). In conjunction with the ...
[84]
Attention neuroenhancement through tDCS or neurofeedback - Nature
Oct 20, 2022 · A systematic review and meta-analysis of the effects of transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal ...
[85]
Non Pharmacological Cognitive Enhancers – Current Perspectives
Jul 1, 2015 · A recent meta-analysis [10] demonstrated that aerobic exercise improves cognitive functions such as memory, processing speed, attention, and ...
[86]
How Realistic Are the Scientific Assumptions of the ... - Frontiers
Jan 21, 2018 · These observations demonstrate that psychopharmacological research is complex, challenging, and difficult even in the case of neurological ...
[87]
Placebo- and Nocebo-Effects in Cognitive Neuroenhancement
Jul 12, 2019 · There is first evidence that the expectation to receive a performance-enhancing drug alone can result in improved perceived and actual cognitive performance.
[88]
Cognition and the Placebo Effect – Dissociating Subjective ...
In this study, we sought to investigate whether placebo and nocebo effects can be evoked in cognitive tasks, and whether these effects influence objective and ...<|control11|><|separator|>
[89]
A comparative review on neuroethical issues in neuroscientific and ...
First, a common limitation of a literature review is so-called publication bias, which leads to successful studies being published more often than unsuccessful ...
[90]
Review Publication and other reporting biases in cognitive sciences
Publication and other reporting biases can have major detrimental effects on the credibility and value of research evidence.
[91]
Reducing publication bias with Registered Reports - Nature
Sep 5, 2024 · This positive publication bias is detrimental to science, as it can skew our understanding of research areas and has the potential to influence ...
[92]
Acute behavioral and physiological effects of modafinil in drug abusers
Modafinil and cocaine dose-dependently increased heart rate and blood pressure. The results of the present study suggest that modafinil has minimal abuse ...
[93]
Consequences of Acute or Chronic Methylphenidate Exposure ...
Aug 2, 2022 · These results indicate that MPH can modulate neurotransmitter efflux in brain regions enriched with dopamine and/or norepinephrine terminals.
[94]
Potential Adverse Effects of Amphetamine Treatment on Brain and ...
Pharmaceutical drugs classed as amphetamines include formulations from salts of d-amphetamine (DextroStat, Dexedrine), mixed d- and l-amphetamine (Adderall™), d ...
[95]
Effects of Caffeine on Cognitive Performance, Mood, and Alertness ...
Higher doses (600 mg) can produce increases in subjects self-ratings of tension or anxiety and increases in caffeine-related physical symptoms (Roache and ...
[96]
Prescription stimulants in individuals with and without attention ...
Finally, we elaborate on the long-term effects of chronic stimulant use. Addiction and tolerance are major concerns, as are psychosis and cardiovascular effects ...
[97]
Nonprescription use of Ritalin linked to adverse side effects, UB ...
May 15, 2017 · Ritalin on those without ADHD showed changes in brain chemistry associated with risk-taking behavior, sleep disruption and other undesirable effects.
[98]
Profiles of Cognitive Dysfunction in Chronic Amphetamine ... - Nature
Aug 1, 2000 · These results indicate that chronic drug use may lead to distinct patterns of cognitive impairment that may be associated with dysfunction of different ...
[99]
Efficacy of stimulants for cognitive enhancement in non-attention ...
There was no overall enhancing effect of amphetamine on cognition; however, amphetamine improved word recall (P = 0.02), convergent creativity (P = 0.01) and ...
[100]
Reinforcing and subjective effects of methylphenidate in adults ... - NIH
Compared to placebo, MPH produced reinforcing effects only for the ADHD group and not for the control group. Increases in stimulant-related subjective effects ...
[101]
Cognitive enhancers - Alcohol and Drug Foundation
Jun 6, 2025 · Side effects · rapid or irregular heartbeat, high blood pressure and potential inflammation of heart valves · skin disorders, vitamin deficiency, ...
[102]
Modafinil - StatPearls - NCBI Bookshelf
Abuse Potential: In clinical trials, modafinil use produces euphoric and psychoactive effects, altering thinking, mood, feelings, and perception like other ...
[103]
Is modafinil safe in the long term? | Drugs - The Guardian
May 31, 2013 · Sahakian's research also suggests that prolific use over a prolonged period of time could have a potentially damaging effect on sleep ...
[104]
The is and ought of the Ethics of Neuroenhancement: Mind the Gap
Ethical views on neuroenhancement are polarized between conservative and liberal theories, with a gap between what 'ought' to be and what 'is' done.
[105]
Against paternalistic views on neuroenhancement: a libertarian ...
Apr 12, 2016 · For its moral specificity, coercive MB interferes tremendously with individual autonomy and freedom without empowering moral competence (Harris, ...
[106]
Neuroethics - Stanford Encyclopedia of Philosophy
Feb 10, 2016 · 1 Autonomy. Cognitive liberty can also be impacted by limiting a person's autonomy. Autonomy is the freedom to be the person one wants to be ...
[107]
[PDF] Liberty and Neuroenhancement in Europe - Tilburg University
legitimate interests of the individual to pursue a private act, and the vulnerability that the individual may have to being harmed by their own autonomy.
[108]
The Social and Economic Impacts of Cognitive Enhancement
Cognitive enhancements can influence the economy through reduction of losses, individual economic benefits, and society-wide benefits.
[109]
[PDF] Transhumanist Thought on Human Enhancement - The Simons Center
Transhumanism aims to remove body/brain constraints, reconfigure human existence using technology to augment the body beyond its natural capacities.
[110]
New breeds of humans: the moral obligation to enhance - PubMed
This paper argues that we have a moral obligation to enhance human beings. It is argued that if one is committed to the moral obligation to treat and prevent ...Missing: neuroenhancement | Show results with:neuroenhancement
[111]
Attitudes toward pharmacological cognitive enhancement—a review
Apr 17, 2014 · First, we discuss equality of opportunity, the fear that inequality in access to enhancement substances might increase inequalities in society.
[112]
[PDF] Neuroenhancement: Is Society Ready? - DigitalCommons@PCOM
It has also been shown that media articles tend to claim that the misuse of methylphenidate and other PCEs are very common in society, especially in an academic.
[113]
Cognitive Enhancement in Education: The State of the Issue
The danger in this scenario would be that individuals in that population may feel pressured or coerced into using cognitive enhancing drugs in order to “measure ...
[114]
Neuroethical issues in pharmacological cognitive enhancement
Jul 28, 2014 · Coercion typically carries the important implications of diminishing the targeted agent's freedom and responsibility, and that it is pro tanto ...
[115]
The Harms of Enhancement and the Conclusive Reasons View - NIH
For example, Michael Sandel bases his case against legitimation almost exclusively on the claim that engaging in bioenhancement expresses an objectionable ...
[116]
The Harms of Enhancement and the Conclusive Reasons View
I assume, as I will henceforth put it, that they are arguing against legitimating bioenhancement. It is notable that Fukuyama, Kass, and Sandel do not engage in ...
[117]
[PDF] Neuroenhancement 1) Article summary - PhilArchive
Sep 14, 2020 · Neuroenhancement is generally defined as the improvement of mental capacities. Such an improvement can be effected via traditional (e.g. ...
[118]
[PDF] To Be or Not to Be Neuroenhanced? - Global Campus Repository
Elliott argues that neuroenhancement inevitably undermines authenticity –'It would be worrying if Prozac altered my personality, even if it gave me a better ...
[119]
[PDF] Why is Cognitive Enhancement Deemed Unacceptable? The Role ...
Feb 19, 2016 · We ask why pharmacological cognitive enhancement (PCE) is generally deemed morally unacceptable by lay people. Our approach to this question ...
[120]
The Prohibited List | World Anti Doping Agency - WADA
Jun 1, 2019 · Eye drops containing beta-blockers are prohibited in particular sports under section P1 because the ophthalmic administration of beta-blockers ...Athletes & Support Personnel · Liste des interdictions · Footer
[121]
The Use and Impact of Cognitive Enhancers among University ...
The impact of stimulant CEs may include tolerance, dependence and/or somatic (e.g., cardiovascular; neurological) complications. Discussion: The availability of ...
[122]
a representative cross-sectional survey among the German population
Oct 22, 2018 · Pharmacological neuroenhancement (PNE) refers to the use of psychoactive substances without medical indication to enhance cognitive performance ...Missing: primary agents
[123]
[Neuroenhancement in four occupations in Germany] - PubMed
Results: The lifetime prevalence of pharmacological neuroenhancement was 8.4%, the 12 months prevalence 2.9% and the 4 weeks prevalence 1.3%. Advertising ...
[124]
The off-prescription use of modafinil: An online survey of perceived ...
Of the 404 respondents, 219 reported taking modafinil. Of these the majority were male, American or British, university-educated and currently employed, with a ...
[125]
The rising use of cognitive enhancement drugs and predictors of use ...
Sample demographics were indicated with number (N), mean (M), standard deviation (SD), and percentage (%) respectively. Self-reported substance use is indicated ...
[126]
The Prevalence of Pharmacological Neuroenhancement Among ...
The 12-month prevalence of PN was 10.4% in 2019, 11.3% in 2020, and 8.0% in 2021. Chi-square tests revealed no statistical difference in the prevalence of PN ...
[127]
Modafinil Really Is a 'Smart Drug,' Study Says - The Atlantic
Aug 27, 2015 · Out of all cognitive processes, modafinil was found to improve decision-making and planning the most in the 24 studies the authors reviewed.Missing: workplace | Show results with:workplace
[128]
Study shows 'smart' drugs can decrease motivation and productivity
May 23, 2023 · In general, participants taking the drugs saw small decreases in accuracy and efficiency, along with large increases in time and effort relative ...Missing: workplace | Show results with:workplace
[129]
'Smart' drugs can decrease productivity in people who don't have ...
Jun 9, 2023 · Smart drugs do motivate people, but the added effort can lead to “erratic thinking”, adversely affecting above-average performers, according to researchers.
[130]
Workers Seeking Productivity in a Pill Are Abusing A.D.H.D. Drugs
Apr 18, 2015 · Dozens of people in a wide spectrum of professions said they and co-workers misused stimulants like Adderall, Vyvanse and Concerta to improve work performance.
[131]
https://www.additudemag.com/prescription-stimulants-methylphenidate-dextroamphetamine-decreases-productivity-adhd/
[132]
Does Adderall Make You Smarter? - Lee Health
Mar 5, 2021 · There's no research to support the expectation that prescription stimulants like Adderall enhance neurocognition and improve academic performance.
[133]
Old Brain, New Tricks - Grey Matters Journal
May 10, 2021 · Neuroenhancement has the potential to widen socioeconomic divides, pose as a barrier to entry to the workforce, and infiltrate our own personal ...
[134]
Sci-fi becomes reality with the rise of 'smart drugs' at work
Jan 30, 2015 · These kinds of drugs suggest opportunities to extend people's working lives, to motivate employees in less stimulating jobs, allow entry to ...
[135]
(PDF) Neuroethical issues in cognitive enhancement: Modafinil as ...
Modafinil not only affects 'cold' cognition, but also improves 'hot' cognition, such as emotion recognition and task-related motivation. The lifestyle use of ' ...
[136]
Can neurotechnology revolutionize cognitive enhancement? - PMC
Oct 29, 2024 · Our view is that a leap in neurotechnology for neuroenhancement can only be achieved if it progresses alongside a more fundamental understanding of human brain ...
[137]
Neurotechnologies for Human Cognitive Augmentation - Frontiers
Deep brain stimulation (DBS) is an invasive brain-stimulation technology widely used for the treatment of movement (e.g., in Parkinson's disease) and memory ...<|control11|><|separator|>
[138]
Clinical Trials - Neuralink
Neuralink's active trials investigate controlling devices with thought for quadriplegia and decoding words from thought for severe speech impairment. An ...
[139]
PRIME Study Progress Update - Neuralink
Apr 12, 2024 · In January, we conducted the first human implantation of our brain-computer interface (BCI). We were able to detect the participant's neural ...
[140]
[PDF] Neuralink's brain-computer interfaces - Frontiers
Mar 24, 2025 · In May 2023, Neuralink received FDA approval (after a rejection in 2022) for human clinical trials but the traditional process of scientific ...
[141]
Brain computer interfaces for cognitive enhancement in older people
Jan 16, 2025 · BCI helps cognitive enhancement in older brains and age-related changes in brain dynamics. One of the most common applications of neuronal ...
[142]
Brain computer interfaces for cognitive enhancement in older people
Jan 16, 2025 · This systematic review addresses BCI applications and challenges in the standard practice of EEG-based neurofeedback (NF) training in healthy older people.
[143]
Bridging Minds and Machines: The Recent Advances of Brain ...
In addition, BCI-based cognitive training has significantly enhanced cognitive functions in dementia patients over the past six weeks, outperforming traditional ...
[144]
UPDATE: Neuralink's Human Tests Progress; Critics Persist
Dec 6, 2023 · “The first human received an implant from Neuralink yesterday and is recovering well,” Musk Tweeted. “Initial results show promising neuron ...
[145]
Mental privacy: navigating risks, rights and regulation: Advances in ...
Jun 25, 2025 · Rapid advances in neurotechnology are eroding the boundary between mental activity and data, creating urgent risks for mental privacy.
[146]
Advancing neurotechnology while protecting the human brain
Oct 1, 2025 · Advancing Neurotechnology while protecting the human brain : A UNESCO Global ethical framework. 1 October 2025 - 2:00 pm - 1 October 2025 - 3:30 ...
[147]
Projections and the Potential Societal Impact of the Future ... - Frontiers
Nov 14, 2021 · These technologies can facilitate functions such as multi-person communication, mood regulation and memory recall. We consider a potential ...
[148]
The Social and Economic Impacts of Cognitive Enhancement
Mar 18, 2011 · Cognitive enhancements can influence the economy through reduction of losses, individual economic benefits, and society-wide benefits. The ...
[149]
Can Neuromodulation also Enhance Social Inequality? Some ...
Mar 7, 2017 · It may raise ethical, social and legal issues related to fairness in selective contexts (exams, competitions, job interviews).Missing: critiques | Show results with:critiques
[150]
What Americans think about possibilities ahead for human ...
Mar 17, 2022 · Even so, many Americans foresee a world where most people would feel social pressure to get these enhancements should they become widespread.